ArticleBMC cancer2018
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.Cancer medicine · 2024Pooled it
- Long-term clinical outcome of lung radiofrequency ablation in patients with musculoskeletal sarcoma.International journal of clinical oncology · 2026Article
- OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway.Journal of experimental & clinical cancer research : CR · 2024Article
- Long non-coding RNA GAS5 promotes cisplatin-chemosensitivity of osteosarcoma cells via microRNA-26b-5p/TP53INP1 axis.Journal of orthopaedic surgery and research · 2023Article
- The COPS3-FOXO3 positive feedback loop regulates autophagy to promote cisplatin resistance in osteosarcoma.Autophagy · 2023Article
- Challenges of Systemic Therapy Investigations for Bone Sarcomas.International journal of molecular sciences · 2022Review
- Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas.Frontiers in oncology · 2022Review
- Identification and Analysis of Three Hub Prognostic Genes Related to Osteosarcoma Metastasis.Journal of oncology · 2021Article
- A review of research progress of antitumor drugs based on tubulin targets.Translational cancer research · 2020Review
- Urothelial carcinoma: Perioperative considerations from top to bottom.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe combination of gemcitabine and docetaxel (GT) has been demonstrated to be effective against various types of solid tumors, including sarcoma. However, the regimen has not been confirmed in large, well-designed clinical trials in refractory metastatic osteosarcoma.
methodsWe retrospectively reviewed the records of patients with refractory metastatic osteosarcoma at Peking University People's Hospital who were treated with gemcitabine (1000 mg/m
resultsA total of 52 patients with a median age of 18.4 years were treated with GT at the Peking University People's Hospital from August 2012 to August 2017. A total of 174 courses were administered. Only five patients with pulmonary metastasis achieved a best response of stable disease (SD), while all other patients had progressive disease. The result was disappointing with an ORR of 0%, a DCR of 9.6%, and a median DOR of 3.5 months. Grade 3 or 4 toxicities were observed in 69 (39.7%) courses and in 28 (53.8%) patients, most of which were myelosuppression, especially thrombocytopenia. No fatal adverse effect (AE) was found.
conclusionThe combination of gemcitabine and docetaxel (GT) as a salvage regimen is well-tolerated but not as effective as expected in refractory metastatic osteosarcoma. This report highlights the need for the development of new approaches with higher activity in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.